A prospective randomized study of Chop versus Chop plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: the International Oncology Study Group NHL1 Study .
The addition of a brief alpha interferon regimen to each CHOP induction cycle, plus one year of alpha interferon thrice weekly maintenance therapy, has no early effect on response rates or survival in patients with Intermediate or High grade cell NHL.


BACKGROUND
The CHOP (Cyclophosphamide, Adriamycin. Vincristine, Prednisone) regimen is the most widely used first-line therapy for patients with Intermediate or High Grade (IG/HG) non-Hodgkin's lymphoma (NHL). Alpha 2b interferon (INF) enhances response rates and improves survival in low-grade NHL. The International Oncology Study Group (IOSG) conducted a prospective randomized study comparing CHOP alone or combined with INF in patients with IG/HG-NHL. The primary study aim was to compare the objective response rates in these patient cohorts.


METHODS
Patients with a confirmed diagnosis of measurable NHL of International Working Formulation (IWF) groups D to H histology were randomized to receive CHOP alone or CHOP with 5Mu INF s.c. for 5 days on days 22 to 26 of each 28 day cycle with INF 5 million units (Mu) given three times per week subcutaneously for 52 weeks in those patients who responded to CHOP plus INF.


RESULTS
The overall response rates were equivalent in both groups: CHOP alone (214 patients) 81% (complete 55%, partial 26%); CHOP plus INF (221 patients) 80% (complete 54%, partial 26%). At 36 months, the actuarial survival rate was equivalent in both groups.


CONCLUSIONS
There is no apparent early advantage in terms of response or survival conferred by adding the study INF regimen to CHOP therapy for patients with IG/HG-NHL.
Giles
F J
FJ
International Oncology Study Group, Houston, Texas, USA. frankgiles@aol.com
Shan
J
J
Advani
S H
SH
Akan
H
H
Aydogdu
I
I
Aziz
Z
Z
Azim
H A
HA
Bapsy
P P
PP
Buyukkececi
F
F
Chaimongkol
B
B
Chen
P M
PM
Cheong
S K
SK
Ferhanoglu
B
B
Hamza
R
R
Khalid
H M
HM
Intragumtornchai
T
T
Kim
S W
SW
Kim
S Y
SY
Koc
H
H
Kumar
L
L
Kumar
R
R
Lei
K I
KI
Lekhakula
A
A
Muthalib
A
A
Patel
M
M
Poovalingam
V P
VP
Prayoonwiwat
W
W
Rana
F
F
Reksodiputro
A H
AH
Ruff
P
P
Sagar
T G
TG
Schwarer
A P
AP
Song
H S
HS
Suh
C W
CW
Suharti
C
C
Supindiman
I
I
Tee
G Y
GY
Thamprasit
T
T
Villalon
A H
AH
Wickham
N R
NR
Wong
J E
JE
Yalcin
A
A
Jootar
S
S
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000633:toxicity; D004317:Doxorubicin / Q000008:administration & dosage / Q000633:toxicity; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000633:toxicity; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage / Q000633:toxicity; D011446:Prospective Studies; D011994:Recombinant Proteins; D015996:Survival Rate; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage / Q000633:toxicity
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone